# Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS

> **NCT05618275** · — · UNKNOWN · sponsor: **University Hospital, Strasbourg, France** · enrollment: 100 (estimated)

## Conditions studied

- BK Virus Infection

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05618275
- **Lead sponsor:** University Hospital, Strasbourg, France
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2022-12
- **Final completion:** 2022-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05618275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05618275, "Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05618275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*